Imperial increases investment in TopiVert

The capital injection brings the total amount committed to TopiVert by Imperial to £8.5m in equity.

The funding round also saw previous investor SV Life Sciences contribute fresh capital, as well as new backers NeoMed Management and Johnson & Johnson Development Corporation.

Previous funding
In December 2011, Imperial and SV Life Sciences backed TopiVert with an £8m early-stage investment.

Company
Headquartered in London, TopiVert is in pre-revenue stages and is currently developing its narrow spectrum kinase inhibitor (NSKI) technology.

The company is aiming to identify new NSKIs for the purpose of creating treatments for inflammatory diseases in the eye and gut, such as uveitis and inflammatory bowel disease (IBS).

People
Maina Bhaman is a director of healthcare investments at Imperial, and also sits on TopiVert's board of directors.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• UK / Ireland
• Early-stage
• Healthcare
• United Kingdom